Union Bancaire Privee UBP SA Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Union Bancaire Privee UBP SA increased its stake in Pfizer Inc. (NYSE:PFE) by 12.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,982 shares of the biopharmaceutical company’s stock after purchasing an additional 20,053 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Pfizer were worth $4,430,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Lipe & Dalton grew its holdings in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 400 shares during the period. Beam Wealth Advisors Inc. boosted its position in Pfizer by 1.5% during the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC grew its holdings in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after purchasing an additional 409 shares during the last quarter. Donaldson Capital Management LLC increased its position in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 410 shares in the last quarter. Finally, Noesis Capital Mangement Corp raised its stake in shares of Pfizer by 2.6% during the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 413 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Trading Up 0.6%

Shares of Pfizer stock opened at $24.46 on Thursday. The firm has a market cap of $139.04 billion, a PE ratio of 17.34, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business’s fifty day moving average is $22.96 and its two-hundred day moving average is $24.98.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company earned $0.82 EPS. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.03%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.